8-K current report · filed Oct 8, 2026

Pacira BioSciences, Inc. (PCRX) 8-K Current Report: October 8, 2026

Item 1.01Item 7.01Item EX-99.1PCRX overview

Short answer

Pacira BioSciences, Inc. (PCRX) filed an 8-K current report with the SEC on October 8, 2026 reporting Item 1.01 (Entry into a Material Definitive Agreement), Item 7.01 (Regulation FD Disclosure), Item EX-99.1 (Exhibit EX-99.1). Viatris agreed to acquire Pacira for $36.50 per share in cash through a tender offer, creating a defined exit value for shareholders.

Pacira BioSciences, Inc. 8-K event analysis

AI summary of each reported item and its exhibits

Item 1.01 · Entry into a Material Definitive Agreement

  • Viatris agreed to acquire Pacira for $36.50 per share in cash through a tender offer, creating a defined exit value for shareholders
  • Tender offer expected within 15 business days, requiring more than 50% shareholder acceptance and HSR antitrust clearance
  • Pacira becomes Viatris’s wholly owned subsidiary without a shareholder vote under Delaware Section 251(h), reducing closing-process uncertainty
  • Equity awards convert to cash at closing, while in-the-money options receive only the spread above their exercise price
  • $62.0 million termination fee payable to Viatris in specified circumstances, including acceptance of a superior offer, limiting competing bids

Item 7.01 · Regulation FD Disclosure

  • Pacira and Viatris announced execution of a merger agreement on October 8, 2026
  • Proposed transaction structured as a tender offer, which has not yet commenced
  • Closing requires valid tenders representing at least a majority of outstanding Pacira shares
  • Investors should await Viatris’ Schedule TO and Pacira’s Schedule 14D-9 for definitive offer terms and board recommendation

Item EX-99.1 · Exhibit EX-99.1

  • Viatris to acquire Pacira for $36.50 cash per share, representing $1.65 billion equity value
  • Pacira contributes $746 million revenue and $177 million adjusted EBITDA for the twelve months ended June 30, 2026
  • Strategic expansion into non-opioid pain therapies through EXPAREL and ZILRETTA, both marketed and patent-protected
  • Funding primarily from excess cash, with remaining consideration from short-term borrowings, minimizing gross leverage impact
  • Closing expected by end of 2026, subject to majority tender and regulatory clearance; Pacira shares then delist from Nasdaq

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other Pacira BioSciences, Inc. 8-K filings

Get the next PCRX 8-K as it lands

Follow PCRX for push alerts, or ask the research agent what this filing means.